Cargando…
Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma
Incomplete surgery of solid tumors is a risk factor for primary treatment failure. Here, we have investigated whether chimeric antigen receptor T cells (CARTs) could be used as an adjuvant therapy to clear residual cancer cells. We tested the feasibility of this approach in two partial resection xen...
Autores principales: | Uslu, Ugur, Da, Tong, Assenmacher, Charles-Antoine, Scholler, John, Young, Regina M., Tchou, Julia, June, Carl H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833675/ https://www.ncbi.nlm.nih.gov/pubmed/36630514 http://dx.doi.org/10.1126/sciadv.ade2526 |
Ejemplares similares
-
Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma
por: Ogunnaike, Edikan A., et al.
Publicado: (2021) -
Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model
por: Liu, Wai Nam, et al.
Publicado: (2022) -
Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL
por: Bai, Zhiliang, et al.
Publicado: (2022) -
Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice
por: Puente-Massaguer, Eduard, et al.
Publicado: (2023) -
Phosphate-mediated coanchoring of RBD immunogens and molecular adjuvants to alum potentiates humoral immunity against SARS-CoV-2
por: Rodrigues, Kristen A., et al.
Publicado: (2021)